{"id":"treatment-with-pcsk9-inhibitors","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Muscle pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that binds to and promotes the degradation of LDL receptors on hepatocytes. By inhibiting PCSK9, these drugs prevent LDL receptor degradation, allowing more receptors to remain on the cell surface. This increases the uptake and clearance of LDL cholesterol from circulation, resulting in significant reductions in plasma LDL-C levels.","oneSentence":"PCSK9 inhibitors block the PCSK9 protein, which normally degrades LDL receptors, thereby increasing LDL receptor availability on liver cells to remove more LDL cholesterol from the blood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:03.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia / elevated LDL cholesterol"},{"name":"Cardiovascular disease risk reduction in patients with elevated LDL-C"}]},"trialDetails":[{"nctId":"NCT07468630","phase":"PHASE2","title":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-10","conditions":"Colon Adenocarcinoma","enrollment":106},{"nctId":"NCT06696820","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Xiang Luo","startDate":"2024-11-29","conditions":"Acute Ischemic Stroke","enrollment":429},{"nctId":"NCT06863545","phase":"NA","title":"Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-22","conditions":"Coronary Artery Disease, CT Angiography, PCSK9","enrollment":3596},{"nctId":"NCT07208006","phase":"NA","title":"Very Early PCSK9 Inhibition for Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-01","conditions":"Acute Myocardial Infarction (AMI)","enrollment":1518},{"nctId":"NCT05430828","phase":"","title":"Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy","status":"RECRUITING","sponsor":"Federico II University","startDate":"2020-03-07","conditions":"Hypercholesterolemia","enrollment":5000},{"nctId":"NCT07295366","phase":"PHASE4","title":"Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2025-11-18","conditions":"Acute Stroke","enrollment":60},{"nctId":"NCT07256197","phase":"PHASE3","title":"PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-01-01","conditions":"Aortic Stenosis, Calcific","enrollment":160},{"nctId":"NCT07290699","phase":"PHASE4","title":"Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2026-01-01","conditions":"STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","enrollment":2442},{"nctId":"NCT07256171","phase":"","title":"COAST Study - Cholesterol Optimization After Stroke","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-01-01","conditions":"Stroke (CVA) or Transient Ischemic Attack, Cerebral Hemorrhage","enrollment":500},{"nctId":"NCT06791031","phase":"NA","title":"PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01","conditions":"Coronary Artery Disease","enrollment":212},{"nctId":"NCT07174375","phase":"PHASE2, PHASE3","title":"PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-09-15","conditions":"Acute Ischemic Stroke","enrollment":478},{"nctId":"NCT06902740","phase":"PHASE4","title":"PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-09-01","conditions":"Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque","enrollment":300},{"nctId":"NCT07084259","phase":"PHASE4","title":"Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Hanyang University Seoul Hospital","startDate":"2025-07","conditions":"Coronary Artery Disease","enrollment":352},{"nctId":"NCT07062328","phase":"PHASE2","title":"A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-10","conditions":"Biliary Tract Carcinoma","enrollment":39},{"nctId":"NCT06930092","phase":"NA","title":"RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-01","conditions":"Ischemic Cardiomyopathy","enrollment":158},{"nctId":"NCT06996223","phase":"EARLY_PHASE1","title":"A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy of PCSK-9 Inhibitors in Delaying the Progression of Calcified Aortic Valve Disease","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-06-01","conditions":"Aortic Stenosis, PCSK9 Inhibitor, Calcified Aortic Valve Disease","enrollment":316},{"nctId":"NCT06604117","phase":"","title":"Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-17","conditions":"Ischemic Stroke, Atherosclerosis of Artery, Lipid Disorder","enrollment":200},{"nctId":"NCT06738758","phase":"","title":"Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-12-16","conditions":"Acute Coronary Syndromes","enrollment":6000},{"nctId":"NCT06854523","phase":"NA","title":"Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)","status":"NOT_YET_RECRUITING","sponsor":"Yun Dai Chen","startDate":"2025-04-15","conditions":"Acute Myocardial Infarction","enrollment":300},{"nctId":"NCT05537948","phase":"PHASE4","title":"Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2021-10-01","conditions":"Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder","enrollment":59},{"nctId":"NCT04369664","phase":"PHASE4","title":"CHOlesterol Lowering and Residual Risk in Type 2 Diabetes","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-12","conditions":"Type 2 Diabetes","enrollment":151},{"nctId":"NCT06520904","phase":"PHASE4","title":"Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography","status":"RECRUITING","sponsor":"First Affiliated Hospital of Xinjiang Medical University","startDate":"2024-07-01","conditions":"Coronary Artery Disease, Optical Coherence Tomography","enrollment":396},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160},{"nctId":"NCT06391905","phase":"PHASE2","title":"PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-05-06","conditions":"Colorectal Cancer","enrollment":60},{"nctId":"NCT06381947","phase":"PHASE4","title":"Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Salerno","startDate":"2024-05-01","conditions":"Dyslipidemias, Statin Adverse Reaction, Cardiovascular Diseases","enrollment":130},{"nctId":"NCT06304987","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-04","conditions":"Locally Advanced Rectal Cancer","enrollment":50},{"nctId":"NCT05624658","phase":"NA","title":"Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS","status":"UNKNOWN","sponsor":"Samara Regional Cardiology Dispensary","startDate":"2022-09-02","conditions":"Dyslipidemias","enrollment":200},{"nctId":"NCT06134635","phase":"","title":"Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-12-01","conditions":"Acute Ischemic Stroke","enrollment":80},{"nctId":"NCT06096909","phase":"NA","title":"Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-01","conditions":"Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":3684},{"nctId":"NCT05976893","phase":"PHASE4","title":"Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer","status":"UNKNOWN","sponsor":"Xiang Xie","startDate":"2023-08-01","conditions":"ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor","enrollment":620},{"nctId":"NCT04608474","phase":"PHASE4","title":"Lipid Management in Renal Transplant Recipients Using Evolocumab.","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-17","conditions":"Hyperlipidemias","enrollment":120},{"nctId":"NCT05802108","phase":"PHASE4","title":"Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy","status":"UNKNOWN","sponsor":"Zibo Central Hospital","startDate":"2022-07-01","conditions":"Adverse Effect of Cardiovascular Medications (Diagnosis)","enrollment":60},{"nctId":"NCT03932721","phase":"PHASE4","title":"EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2018-10-01","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension Arterial","enrollment":110},{"nctId":"NCT03933293","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH","status":"COMPLETED","sponsor":"Akeso","startDate":"2019-05-13","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":10},{"nctId":"NCT04319081","phase":"","title":"Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors","status":"COMPLETED","sponsor":"Jose Seijas Amigo","startDate":"2020-03-01","conditions":"Cognitive Function, Hypercholesterolemia, Quality of Life","enrollment":180},{"nctId":"NCT01380730","phase":"PHASE2","title":"LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-01","conditions":"Hyperlipidemia","enrollment":631},{"nctId":"NCT05298475","phase":"PHASE4","title":"Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-04-01","conditions":"Acute Coronary Syndrome","enrollment":100},{"nctId":"NCT05081336","phase":"","title":"Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry","status":"UNKNOWN","sponsor":"University Clinical Centre of Republic of Srpska","startDate":"2021-03-01","conditions":"Acute Coronary Syndrome, Dyslipidemias","enrollment":500},{"nctId":"NCT04197453","phase":"","title":"The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-12-06","conditions":"ASCVD","enrollment":752},{"nctId":"NCT04759534","phase":"PHASE3","title":"Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2020-09-10","conditions":"Efficacy and Safety, Heterozygous Familial Hypercholesterolemia, PCSK9","enrollment":20},{"nctId":"NCT04851769","phase":"PHASE4","title":"Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2019-03-02","conditions":"Randomized Controlled Trials","enrollment":60},{"nctId":"NCT01859455","phase":"PHASE1","title":"Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-07","conditions":"Hypercholesterolemia, LDL Cholesterol","enrollment":25},{"nctId":"NCT02941016","phase":"PHASE4","title":"Vascular Inflammation and Cholesterol Lowering Therapy","status":"WITHDRAWN","sponsor":"Rigshospitalet, Denmark","startDate":"2016-10","conditions":"Lipid Lowering, Vascular Inflammation","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1839,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Treatment with Proprotein convertase subtilisin/kexin type 9 inhibitors"],"phase":"phase_3","status":"active","brandName":"Treatment with PCSK9 inhibitors","genericName":"Treatment with PCSK9 inhibitors","companyName":"Beijing Anzhen Hospital","companyId":"beijing-anzhen-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PCSK9 inhibitors block the PCSK9 protein, which normally degrades LDL receptors, thereby increasing LDL receptor availability on liver cells to remove more LDL cholesterol from the blood. Used for Hypercholesterolemia / elevated LDL cholesterol, Cardiovascular disease risk reduction in patients with elevated LDL-C.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}